SAMe (S-adenosylmethionine)

S-adenosylmethionine is the molecule the body makes from methionine to carry methyl groups, and it sits one step downstream of betaine in the pathway. That is how it reaches this guide at all — but the case for SAMe and cartilage is a separate one from the methylation story, and it rests on something much smaller than the pathway does.

The mechanism, and how thin it is

In 1987, human osteoarthritic chondrocytes were grown in thick-layer culture and exposed to SAMe at three concentrations. At 10 micrograms per millilitre — the most effective of the three — incorporation of labelled sulfate and labelled serine rose significantly and hexuronic acid content increased, which the authors read as more active protein synthesis and particularly more proteoglycan synthesis. The proliferation rate of the cells barely moved.

That is the entire mechanistic case, and the authors were candid about its limits: they concluded that the results point to a direct action on cell metabolism and that little is known about the mechanism involved. Nothing since has followed it into an animal model or into a human joint.

What the placebo-controlled trials found

Four randomised placebo-controlled trials of SAMe in knee or hip osteoarthritis exist, covering 656 patients between them, and Cochrane pooled all four.

Pain came to a standardised mean difference of -0.17, with a 95% confidence interval from -0.34 to 0.01 — which the review translates as 0.4 cm on a 10 cm visual analogue scale. The between-trial heterogeneity was zero, so the four trials agreed with each other about a small and imprecise effect. Function came to 0.02, with an interval running from -0.68 to 0.71.

Cochrane rated the methodological quality and the quality of reporting poor, and advised against routine use.

The largest of those four was also the field's flagship: 734 patients across 33 Italian centres, comparing SAMe 1,200 mg daily with naproxen 750 mg daily and with placebo. SAMe produced the same analgesic activity as naproxen, both active arms separated from placebo, and tolerability favoured SAMe on the physicians' assessment, the patients' assessment and the count of patients reporting side effects. SAMe and placebo produced the same number of side effects as each other.

The trials that make up most of the literature

Nearly every other SAMe trial in this disease uses an anti-inflammatory drug as its comparator rather than a placebo. That makes the literature much larger than four trials, and much less able to answer whether SAMe beats doing nothing.

• 150 patients, SAMe against ibuprofen for thirty days: SAMe showed slightly more marked activity across the painful manifestations, with minor side effects in five patients on SAMe and sixteen on ibuprofen, and no dropouts from either arm.
• 36 subjects, SAMe against ibuprofen for four weeks: the summed score for morning stiffness, pain at rest, pain on motion, crepitus, swelling and limitation of motion improved to the same extent in both arms.
• 61 adults, SAMe against celecoxib in a sixteen-week crossover: celecoxib was ahead in the first month and the two were level by the second.
• 134 Korean patients, SAMe against nabumetone for eight weeks: pain fell 13.0 mm and 15.7 mm on a visual analogue scale, both significant from baseline and not different from each other.

The pattern across all four is the same, and it is a real finding rather than a consolation: SAMe arrives where an anti-inflammatory arrives, takes longer to get there, and upsets fewer stomachs. What the pattern cannot establish is whether either arm is doing anything a placebo would not, because none of these trials has one.

One more trial sits awkwardly between the two groups. Eighty-one patients received intravenous SAMe for five days and then oral SAMe for twenty-three, against a matching placebo regimen. At the centre where disease was milder and the arms were well matched, SAMe significantly reduced overall pain and rest pain. At the other centre, where randomisation produced markedly different groups, nothing separated. The result depends on which half of the trial is read, which the authors say themselves.

What most people take it for

The larger and better SAMe literature is about mood, and this guide covers it because that is what a person swallowing SAMe is usually relying on.

Across 23 randomised trials and 2,183 participants, SAMe on its own separated from placebo on depressive symptoms with a standardised mean difference of -0.58. Added on top of an antidepressant it added nothing detectable, and set against an antidepressant alone it was indistinguishable. Dropout rates did not differ in any of the three comparisons, and the authors rate the certainty moderate.

Those records carry the non-joint-endpoint tag, so they inform this page and can never lift its cartilage tier. The scope point is worth making plainly: SAMe has moderate evidence for one thing and equivocal evidence for another, and this guide grades the second.

Practical notes

Every osteoarthritis trial recorded here used 1,200 mg a day, usually as 400 mg three times. Onset is slow — the celecoxib crossover found SAMe behind at one month and level at two, and the intravenous trial saw effects from fourteen days — so a four-week judgement is likely to be an unfair one.

The trials ran between four and sixteen weeks, and none ran longer. That is worth knowing about a supplement people take for years.

Tolerability is the most consistent positive result in this literature. In the largest trial SAMe produced the same number of side effects as placebo and fewer than naproxen; in the ibuprofen comparison, five patients against sixteen; in the nabumetone comparison, adverse events in 35.8% and 31.3% of the two arms.

One caution this guide cannot source and therefore does not state as a finding: the mood literature is the reason SAMe gets discussed alongside antidepressants, and the interaction questions that follow — serotonergic drugs, and use in bipolar disorder — are not addressed by any record here. Anyone on psychiatric medication needs a clinician rather than a page.

What would move the tier

A modern, adequately powered, placebo-controlled trial. The whole placebo-controlled evidence base predates 1995 and was rated poor by the people who pooled it, so the question of whether SAMe beats nothing for a knee has not so much been answered as never properly asked — and a compound that holds its own against celecoxib and naproxen on tolerability is worth asking properly about.

The more interesting study is smaller and cheaper. The proteoglycan finding that started all of this has never been carried past cell culture; an animal model with a cartilage endpoint, or a human trial with a biomarker like CTX-II, would say whether there is anything structural here at all — and either result would be worth having.